How to Qualify for Zepbound: Eligibility Criteria

Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults who meet one of two body mass index thresholds: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related medical condition. Those thresholds sound straightforward, but the path from “technically eligible” to actually receiving the medication involves your doctor, your insurance plan, and a set of safety screenings that can trip people up.

The Two BMI Cutoffs

The eligibility criteria for Zepbound mirror the standard FDA framework used for prescription weight-management medications. If your BMI is 30 or above, you qualify on that basis alone. If your BMI falls between 27 and 29.9, you need a documented weight-related comorbidity to be eligible. Your doctor calculates BMI from your height and weight at the time of evaluation, so the number on the chart that day is what counts.

A BMI of 30 corresponds to roughly 210 pounds for someone who is 5’9″, or about 180 pounds at 5’4″. A BMI of 27 lands at around 183 pounds for a 5’9″ person. These are approximate figures because BMI does not distinguish between muscle mass and fat mass, but they give a general sense of where the cutoffs fall in everyday terms. Your prescriber uses the standard calculation regardless of body composition.

Which Weight-Related Conditions Count

If your BMI is between 27 and 29.9, you need at least one qualifying comorbidity. The FDA label lists conditions that are caused or worsened by excess weight. The most common ones include:

High blood pressure: diagnosed hypertension or use of antihypertensive medication.
Type 2 diabetes: an established diagnosis, though Zepbound is approved specifically for weight management rather than blood sugar control. (Eli Lilly’s separate brand, Mounjaro, uses the same molecule for type 2 diabetes.)
High cholesterol or triglycerides: dyslipidemia documented through bloodwork.
Obstructive sleep apnea: a diagnosis confirmed by a sleep study.
Cardiovascular disease: a history of heart disease or related vascular conditions.

You do not need to have all of these. One documented condition is enough. In clinical practice, many patients with a BMI above 27 already carry at least one of these diagnoses, so the comorbidity requirement often does not present a barrier once a prescriber reviews your medical history.

What Happens During the Prescriber Visit

Zepbound requires a prescription. You cannot buy it over the counter or order it without a clinician’s involvement. During the visit, your prescriber will check your BMI, review your medical history for qualifying comorbidities, and screen for contraindications. This visit can happen in person or through a telehealth platform, since many online weight-management services now prescribe tirzepatide after a virtual evaluation.

Expect your prescriber to ask about your weight history, previous attempts at diet and exercise, and any medications you currently take. They will also want to know about your family history of certain cancers, particularly thyroid cancer, because that is relevant to the drug’s safety profile. If you have had bariatric surgery, let your provider know, as it can affect how the medication is absorbed and tolerated.

Zepbound is started at a low dose of 2.5 mg per week for the first four weeks, then gradually increased. The target maintenance dose ranges from 5 mg to 15 mg per week, and your prescriber will adjust the dose based on how you respond and what side effects you experience. This titration schedule is built into the approval, so a provider who skips it or rushes it is not following the label.

Insurance Coverage and Prior Authorization

Meeting the FDA’s medical eligibility criteria does not guarantee your insurance will pay for Zepbound. Many commercial insurance plans, Medicare Part D plans, and Medicaid programs have their own coverage policies for anti-obesity medications, and these policies are inconsistent. Some plans cover Zepbound with prior authorization, some exclude it entirely, and some cover it only after you have tried and failed other weight-loss interventions.

Prior authorization typically requires your prescriber to submit documentation showing that you meet the BMI threshold, have a qualifying comorbidity (if applicable), and have attempted lifestyle modifications such as diet and exercise. Some insurers also require that you have tried other weight-management medications first, a practice known as step therapy. If your plan denies coverage, your prescriber can file an appeal, though success varies.

Without insurance coverage, Zepbound’s list price is over $1,000 per month. Eli Lilly has offered savings programs for commercially insured patients, and the company launched a direct-to-consumer option called LillyDirect that sells certain doses at a reduced cash price. These programs change frequently, so the specifics at the time you fill your prescription may differ from what was available a few months earlier.

Who Should Not Take Zepbound

Certain conditions disqualify you from taking Zepbound regardless of your BMI. The most important contraindication is a personal or family history of medullary thyroid carcinoma, a rare type of thyroid cancer. In animal studies, tirzepatide and related drugs caused thyroid C-cell tumors. Whether this risk translates to humans is not fully established, but the FDA labeling carries a boxed warning, and prescribers are instructed not to give the drug to anyone with this cancer history or with a condition called Multiple Endocrine Neoplasia syndrome type 2.

A known serious allergic reaction to tirzepatide or any of its ingredients is also a disqualifier. Beyond those absolute contraindications, several conditions require extra caution. People with a history of pancreatitis should discuss risks carefully with their provider. A systematic review found that tirzepatide was not associated with a statistically significant increase in pancreatitis risk compared to control groups, but the overall evidence base is still relatively small, and prescribers tend to be conservative with patients who have had pancreatic inflammation before.¹

Gallbladder disease is a more concrete concern. The same review found that tirzepatide was associated with roughly double the risk of gallbladder or biliary disease compared to placebo or basal insulin.¹ Rapid weight loss itself increases gallstone risk, so this is not unique to tirzepatide, but the finding is worth knowing if you have a history of gallbladder problems.

Pregnancy is another disqualification. Zepbound should be stopped at least two months before a planned pregnancy, and it is not approved for use during pregnancy or breastfeeding. The drug’s effect on appetite and caloric intake could restrict fetal nutrition, and there is not enough safety data in pregnant women to support its use.

Common Side Effects and What They Mean for Eligibility

Gastrointestinal symptoms are the most frequently reported side effects: nausea, diarrhea, constipation, and vomiting. These tend to be worst during the dose-escalation phase and improve for most people as their body adjusts. A review of GLP-1 and dual-agonist medications noted that more serious but less common gastrointestinal risks include delayed gastric emptying, gastroparesis-like symptoms, and intestinal obstruction.²

These side effects do not usually prevent someone from qualifying for the medication, but they can lead to dose reductions or discontinuation after starting. If you already have gastroparesis or severe gastrointestinal motility problems, your prescriber may decide the risks outweigh the benefits. The eligibility decision in borderline cases comes down to clinical judgment rather than a rigid checklist.

How Much Weight Loss the Clinical Trials Show

Understanding what Zepbound can realistically achieve helps explain why the eligibility bar is set where it is and what your prescriber is evaluating when they write the prescription. In the pivotal SURMOUNT-1 trial, participants without type 2 diabetes lost an average of about 15% of their body weight on the 5 mg dose, roughly 20% on the 10 mg dose, and about 21% on the 15 mg dose over 72 weeks, compared to about 3% with placebo.³ More than half of participants on the two higher doses lost at least 20% of their starting weight.³

A body composition analysis from the same trial showed that roughly three-quarters of the weight lost was fat mass and about a quarter was lean mass, a ratio that held for both the medication and placebo groups.⁴ Losing some lean mass during significant weight loss is expected, but the proportion matters because excessive muscle loss can undermine physical function, especially in older adults.

Real-world data generally confirms the trial findings, though the numbers tend to be slightly lower outside a controlled study setting. A six-month retrospective study of nearly 2,400 patients found that tirzepatide users lost about 11% of their body weight on average, compared to about 9% for semaglutide users, with greater reductions in BMI, blood pressure, and hemoglobin A1c.⁵ The gap between trial results and real-world results likely reflects shorter follow-up periods, variable dose titration, and differences in adherence when patients are paying out of pocket or dealing with supply issues.

How Zepbound Compares to Other Weight-Loss Medications

If you are exploring your options, you may wonder whether the eligibility criteria differ between Zepbound and medications like Wegovy (semaglutide). The BMI thresholds are the same across FDA-approved anti-obesity medications: BMI of 30 or higher, or 27 or higher with a comorbidity. The difference is in what each drug does once you are on it.

A Bayesian network meta-analysis comparing tirzepatide to semaglutide and liraglutide in people with obesity but without type 2 diabetes found that the 10 mg and 15 mg doses of tirzepatide produced significantly greater weight reduction than either comparator. The difference over semaglutide was roughly 5 to 6 additional percentage points of weight lost, and the safety profiles were comparable across all three drugs.⁶ A separate network meta-analysis ranked tirzepatide 15 mg as producing the greatest percentage weight reduction among currently available agents, at roughly 18%.⁷

From a practical standpoint, your insurance plan’s formulary often determines which medication you end up on more than clinical preference does. Some plans cover Wegovy but not Zepbound, or vice versa. If one is denied, your prescriber may switch you to the other without needing to re-establish eligibility from scratch, since the qualifying criteria are the same.

Why Zepbound Is Meant to Be Long-Term

One point that catches people off guard is that Zepbound is not designed as a short-term fix. The clinical evidence consistently shows that weight returns when the medication is stopped. In the SURMOUNT-4 trial, participants who had lost an average of about 21% of their body weight during a 36-week treatment period were then randomized to either continue tirzepatide or switch to placebo. Those who continued lost an additional 5.5% over the following year, while those switched to placebo regained an average of 14%.⁸ About 90% of people who stayed on tirzepatide maintained at least 80% of their initial weight loss, compared to fewer than 17% of those given placebo.⁸

A narrative review of weight regain across GLP-1 and dual-agonist medications found that this pattern of rapid rebound is consistent regardless of which medication was used or how long the initial treatment lasted.⁹ A post hoc analysis of SURMOUNT-4 further noted that the cardiometabolic improvements achieved during treatment, such as lower blood pressure and improved blood sugar, also reversed when the drug was withdrawn.¹⁰

This has direct implications for your eligibility planning. If you qualify, start the medication, and then lose insurance coverage or can no longer afford it, you should expect much of the weight to come back. That reality is worth factoring into your decision, especially if your insurance coverage is uncertain or your plan requires annual reauthorization.

Older Adults and Other Special Populations

The FDA approval does not set an upper age limit for Zepbound, but prescribers approach older adults with extra care. In this population, muscle mass loss during weight reduction is a particular concern because sarcopenia (age-related muscle decline) already puts older adults at higher risk of falls and functional decline. Researchers have pointed out that more drug trials in older adults are needed, focusing not just on the number on the scale but on muscle preservation, bone quality, and changes in how fat is distributed.¹¹ If you are over 65 and considering Zepbound, your prescriber will likely emphasize resistance exercise alongside the medication to minimize lean-mass loss.

Adolescents are another group where eligibility is evolving. As of mid-2025, Zepbound’s FDA approval applies to adults aged 18 and older. Clinical trials in younger populations are underway, but the drug is not currently approved for anyone under 18. Some prescribers do use tirzepatide off-label in adolescents with severe obesity, though this is done on a case-by-case basis and is not supported by the same level of evidence as the adult approval.

The Problem With Compounded Tirzepatide

During periods of drug shortage, compounding pharmacies have produced their own versions of tirzepatide, often marketed at lower prices. These products are not FDA-approved and are not subject to the same manufacturing standards as brand-name Zepbound. A recent analysis of mass-compounded tirzepatide/B12 products found a novel impurity present at substantial levels, one that does not appear in the approved product and whose clinical effects are unknown.¹² Despite being marketed as “personalized” treatments, these compounded products are essentially untested formulations sold outside the drug-approval framework.

If you are considering compounded tirzepatide because of cost or availability, understand that you are taking on additional risk. The eligibility criteria we have discussed apply to the FDA-approved product, and your prescriber’s safety screening is calibrated around a drug whose composition is known and consistent. Compounded products may vary batch to batch, and the rising off-label use of weight-loss medications through nontraditional channels has raised safety concerns among pharmacists and regulators.¹³

Obstructive Sleep Apnea and an Expanding Role

In late 2024, the FDA approved Zepbound for a second indication: the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This is relevant to eligibility because it creates another pathway to a prescription. If you have both obesity and obstructive sleep apnea, your prescriber can now prescribe Zepbound specifically for the sleep apnea, not only for weight management.

The approval was based on the SURMOUNT-OSA trials, which enrolled adults with a BMI of 30 or above and moderate-to-severe sleep apnea.¹⁴ Over 52 weeks, tirzepatide reduced the number of breathing interruptions per hour by about 20 to 24 events more than placebo, a clinically meaningful improvement that in some cases moved participants from severe to mild sleep apnea categories.¹⁵ Improvements in blood pressure, body weight, and patient-reported sleep quality accompanied the reduction in apnea events.

From an insurance perspective, this second indication can sometimes work in your favor. If your plan does not cover anti-obesity medications but does cover treatments for sleep apnea, the sleep apnea indication may provide an alternate route to coverage. Your prescriber and their staff can help navigate which diagnostic code to use when submitting the prior authorization request.

Benefits Beyond the Scale

Part of why prescribers are willing to write Zepbound prescriptions extends beyond raw weight loss. A narrative review of tirzepatide’s cardiometabolic effects found consistent reductions in systolic blood pressure of roughly 4 to 6 mmHg and diastolic pressure of about 2 mmHg across the major trials. In the SURMOUNT-1 obesity trial, about 58% of tirzepatide-treated participants reached normal blood pressure (below 130/80) by 72 weeks, compared to 35% on placebo.¹⁶ Improvements in triglycerides, cholesterol markers, and hemoglobin A1c have been documented across trials in both diabetic and non-diabetic populations.¹⁷

These secondary benefits are relevant to your eligibility conversation because they give your prescriber clinical reasons to advocate for the medication beyond the number on the scale. If you have borderline blood pressure or prediabetes alongside a qualifying BMI, the downstream cardiometabolic effects strengthen the case for treatment and can make prior authorization appeals more persuasive. The eligibility criteria get you in the door, but the breadth of clinical benefit is often what keeps the prescription going.